Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxy) ethylamino-12,13-dihydro-13-(β-D-gluco pyranosyl)-5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione] against pediatric and adult central nervous system tumor xenografts

Cancer Chemotherapy and Pharmacology

Volumn 48, Issue 3, 2001, Pages 250-254

  Cavazos, C M ^a   Keir, S T ^a   Yoshinari, T ^a   Bigner, D D ^a   Friedman, H S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Central nervous system tumors; J 107088; Topoisomerase I inhibitors; Xenografts

Indexed keywords

6 N (1 HYDROXYMETHYL 2 HYDROXY)ETHYLAMINO 12,13 DIHYDRO 13 (BETA DEXTRO GLUCOPYRANOSYL) 5H INDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE; ANTINEOPLASTIC AGENT; DIMETHYL SULFOXIDE; EDOTECARIN; PROCARBAZINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER REGRESSION; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; MALE; MEDULLOBLASTOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ADULT; ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARBAZOLES; CHILD; DNA TOPOISOMERASES, TYPE I; ENZYME INHIBITORS; FEMALE; GLIOMA; GLUCOSIDES; HUMANS; INDOLES; INJECTIONS, INTRAPERITONEAL; INJECTIONS, SUBCUTANEOUS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 0034884824     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800100347     Document Type: Article

References (18)

1. Novel antitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(β-D-glucopyranosyl) 5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole5,7-(6H)-dione (NB-506): Its potent antitumor activity in mice
2. In vivo antitumor activity of a novel indolocarbazole compound, J-107088, on murine and human tumors transplanted into mice
3. The heterotransplantation of human craniopharyngiomas in athymic "nude" mice
4. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults
5. Chemotherapy of subcutaneous and intracranial human medulloblastoma xenografts in athymic nude mice
6. Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents
7. Activity of 9-dimethyl-aminomethyl-10-hydroxy camptothecin against pediatric and adult central nervous system tumor xenografts
8. Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft
9. Topotecan treatment of adults with primary malignant glioma
10. Irinotecan therapy in adults with recurrent or progressive malignant glioma
11. Sequence-selective DNA cleavage by topoisomerase I poison
12. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic and phenobarbital
13. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4[1-piperidino)-carbonyloxy camptothecin against pediatric and adult central nervous system tumor xenografts
14. Clinical pharmacokinetics of topotecan in children with cancer
15. Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the anti-proliferative activity of the indolocarbazole, NB-506 and its topoisomerase 1 binding site
16. Novel antitumor · 1,11-dihydroxy-13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]-pyrrolo[3,4-c] carbazole-5.7(6H)-dione (NB-506): Induction of topoisomerase I-mediated DNA cleavage arid mechanisms of cell line-selective cytotoxicity
17. Mode of action of it new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I
18. Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma